OrbiMed’s Adicet Bio ACET Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7M | Hold |
1,027,944
| – | – | 0.14% | 87 |
|
|
2025
Q4 | $8.66M | Buy |
1,027,944
+312,498
| +44% | +$3.45M | 0.18% | 82 |
|
|
2025
Q3 | $9.27M | Hold |
715,446
| – | – | 0.22% | 75 |
|
|
2025
Q2 | $6.98M | Hold |
715,446
| – | – | 0.17% | 70 |
|
|
2025
Q1 | $8.64M | Hold |
715,446
| – | – | 0.21% | 65 |
|
|
2024
Q4 | $11M | Hold |
715,446
| – | – | 0.23% | 70 |
|
|
2024
Q3 | $16.5M | Hold |
715,446
| – | – | 0.3% | 71 |
|
|
2024
Q2 | $13.9M | Hold |
715,446
| – | – | 0.27% | 65 |
|
|
2024
Q1 | $26.9M | Buy |
715,446
+195,312
| +38% | +$8.08M | 0.49% | 56 |
|
|
2023
Q4 | $15.7M | Hold |
520,134
| – | – | 0.31% | 68 |
|
|
2023
Q3 | $11.4M | Hold |
520,134
| – | – | 0.24% | 79 |
|
|
2023
Q2 | $20.2M | Buy |
520,134
+54,688
| +12% | +$4.83M | 0.37% | 70 |
|
|
2023
Q1 | $42.9M | Hold |
465,446
| – | – | 0.84% | 40 |
|
|
2022
Q4 | $66.6M | Hold |
465,446
| – | – | 1.27% | 27 |
|
|
2022
Q3 | $106K | Hold |
465,446
| – | – | 1.97% | 14 |
|
|
2022
Q2 | $109K | Hold |
465,446
| – | – | 1.97% | 15 |
|
|
2022
Q1 | $149M | Hold |
465,446
| – | – | 2.41% | 10 |
|
|
2021
Q4 | $130M | Buy |
465,446
+13,392
| +3% | +$2.3M | 1.67% | 19 |
|
|
2021
Q3 | $56.7M | Hold |
452,054
| – | – | 0.62% | 48 |
|
|
2021
Q2 | $74.4M | Hold |
452,054
| – | – | 0.75% | 44 |
|
|
2021
Q1 | $94.6M | Buy |
452,054
+32,772
| +8% | +$7.52M | 0.88% | 33 |
|
|
2020
Q4 | $94.3M | Hold |
419,282
| – | – | 0.82% | 36 |
|
|
2020
Q3 | $79.8M | Buy |
419,282
+376,154
| +872% | +$95.1M | 1% | 29 |
|
|
2020
Q2 | $10.4M | Hold |
43,128
| – | – | 0.15% | 98 |
|
|
2020
Q1 | $4.97M | Hold |
43,128
| – | – | 0.08% | 106 |
|
|
2019
Q4 | $7.2M | Hold |
43,128
| – | – | 0.1% | 89 |
|
|
2019
Q3 | $42.7M | Hold |
43,128
| – | – | 0.81% | 40 |
|
|
2019
Q2 | $49.3M | Hold |
43,128
| – | – | 0.76% | 40 |
|
|
2019
Q1 | $32.9M | Hold |
43,128
| – | – | 0.51% | 53 |
|
|
2018
Q4 | $41.6M | Hold |
43,128
| – | – | 0.77% | 42 |
|
|
2018
Q3 | $73.1M | Hold |
43,128
| – | – | 0.88% | 33 |
|
|
2018
Q2 | $44.2M | Hold |
43,128
| – | – | 0.53% | 55 |
|
|
2018
Q1 | $46.3M | Buy |
+43,128
| New | +$79.1M | 0.57% | 52 |
|
Other funds holding ACET
RCM
VCM
WP
PM
SCM
OrbiMed's ACET Position: Q1 2026 in Review
OrbiMed held its Adicet Bio (ACET) position steady in Q1 2026 at 1,027,944 shares worth $7M. The position accounts for 0.14% of the portfolio, ranked #87.
OrbiMed first reported a position in ACET in Q1 2018 and has held it in 33 quarters since. The position peaked at $149M in Q1 2022. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.
- OrbiMed held 1,027,944 shares of Adicet Bio worth $7M as of Q1 2026.
- OrbiMed left its Adicet Bio share count unchanged in Q1 2026.
- Adicet Bio made up 0.14% of OrbiMed's portfolio in Q1 2026, its #87 holding.
- OrbiMed first reported a position in Adicet Bio in Q1 2018 and has held it in 33 quarters since.
- OrbiMed's Adicet Bio position peaked at $149M in Q1 2022.
- 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.
Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.